Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 621.00K | 358.50K | 133.30K | 133.30K | 149.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.15M | 879.30K | 559.70K | 559.70K | 566.90K |
| Operating Income | -1.15M | -879.30K | -559.70K | -559.70K | -566.90K |
| Income Before Tax | -1.81M | -1.52M | -939.70K | -939.70K | -857.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.81M | -1.52M | -939.70K | -939.70K | -857.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.81M | -1.52M | -939.70K | -939.70K | -857.40K |
| EBIT | -1.15M | -879.30K | -559.70K | -559.70K | -566.90K |
| EBITDA | -1.15M | -875.20K | -552.30K | -544.40K | -535.90K |
| EPS Basic | -12.96 | -10.90 | -6.75 | -6.75 | -6.16 |
| Normalized Basic EPS | -6.48 | -5.27 | -3.35 | -3.35 | -3.38 |
| EPS Diluted | -12.96 | -10.90 | -6.75 | -6.75 | -6.16 |
| Normalized Diluted EPS | -6.48 | -5.27 | -3.35 | -3.35 | -3.38 |
| Average Basic Shares Outstanding | 139.30K | 139.30K | 139.30K | 139.30K | 139.20K |
| Average Diluted Shares Outstanding | 139.30K | 139.30K | 139.30K | 139.30K | 139.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |